Literature DB >> 21576649

Casein kinase-2α1 induces hypertrophic response by phosphorylation of histone deacetylase 2 S394 and its activation in the heart.

Gwang Hyeon Eom1, Young Kuk Cho, Jeong-Hyeon Ko, Sera Shin, Nakwon Choe, Yoojung Kim, Hosouk Joung, Hyung-Seok Kim, Kwang-Il Nam, Hae Jin Kee, Hyun Kook.   

Abstract

BACKGROUND: Cardiac hypertrophy is characterized by transcriptional reprogramming of fetal gene expression, and histone deacetylases (HDACs) are tightly linked to the regulation of those genes. We previously demonstrated that activation of HDAC2, 1 of the class I HDACs, mediates hypertrophy. Here, we show that casein kinase-2α1 (CK2α1)-dependent phosphorylation of HDAC2 S394 is required for the development of cardiac hypertrophy. METHODS AND
RESULTS: Hypertrophic stimuli phosphorylated HDAC2 S394, which was necessary for its enzymatic activation, and therefore the development of hypertrophic phenotypes in rat neonatal cardiomyocytes or in isoproterenol-administered mice hearts. Transgenic mice overexpressing HDAC2 wild type exhibited cardiac hypertrophy, whereas those expressing phosphorylation-resistant HDAC2 S394A did not. Compared with that in age-matched normal human hearts, phosphorylation of HDAC2 S394 was dramatically increased in patients with hypertrophic cardiomyopathy. Hypertrophy-induced phosphorylation of HDAC2 S394 and its enzymatic activity were completely blocked either by CK2 blockers or by CK2α1 short interfering RNA. Hypertrophic stimuli led CK2α1 to be activated, and its chemical inhibitors blocked hypertrophy in both phenylephrine-treated cardiomyocytes and isoproterenol-administered mice. CK2α1-transgenic mice developed hypertrophy, which was attenuated by administration of trichostatin A, an HDAC inhibitor. Overexpression of CK2α1 caused hypertrophy in cardiomyocytes, whereas chemical inhibitors of both CK2 and HDAC as well as HDAC2 S394A blunted it. Hypertrophy in CK2α1-transgenic mice was exaggerated by crossing these mice with wild-type-HDAC2-overexpressing mice. By contrast, however, it was blocked when CK2α1-transgenic mice were crossed with HDAC2 S394A-transgenic mice.
CONCLUSIONS: We have demonstrated a novel mechanism in the development of cardiac hypertrophy by which CK2 activates HDAC2 via phosphorylating HDAC2 S394.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21576649     DOI: 10.1161/CIRCULATIONAHA.110.003665

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  42 in total

1.  Selective class I histone deacetylase inhibition suppresses hypoxia-induced cardiopulmonary remodeling through an antiproliferative mechanism.

Authors:  Maria A Cavasin; Kim Demos-Davies; Todd R Horn; Lori A Walker; Douglas D Lemon; Nicholas Birdsey; Mary C M Weiser-Evans; Julie Harral; David C Irwin; Adil Anwar; Michael E Yeager; Min Li; Peter A Watson; Raphael A Nemenoff; Peter M Buttrick; Kurt R Stenmark; Timothy A McKinsey
Journal:  Circ Res       Date:  2012-01-26       Impact factor: 17.367

2.  HDACs and hypertrophy, kinases and cancer.

Authors:  Berdymammet Hojayev; Joseph A Hill
Journal:  Circulation       Date:  2011-05-16       Impact factor: 29.690

3.  Phosphorylation of Histone Deacetylase 8: Structural and Mechanistic Analysis of the Phosphomimetic S39E Mutant.

Authors:  Katherine R Welker Leng; Carol Ann Castañeda; Christophe Decroos; Barira Islam; Shozeb M Haider; David W Christianson; Carol A Fierke
Journal:  Biochemistry       Date:  2019-11-04       Impact factor: 3.162

Review 4.  Epigenetic regulation of cardiac fibrosis.

Authors:  Matthew S Stratton; Timothy A McKinsey
Journal:  J Mol Cell Cardiol       Date:  2016-02-12       Impact factor: 5.000

5.  Vitexin protects against cardiac hypertrophy via inhibiting calcineurin and CaMKII signaling pathways.

Authors:  Cui-cui Lu; Ying-qi Xu; Ji-chao Wu; Peng-zhou Hang; Yan Wang; Chen Wang; Jian-wei Wu; Jian-cui Qi; Yong Zhang; Zhi-min Du
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-04-28       Impact factor: 3.000

Review 6.  Genetic cardiomyopathies. Lessons learned from humans, mice, and zebrafish.

Authors:  W Kloos; H A Katus; B Meder
Journal:  Herz       Date:  2012-09       Impact factor: 1.443

Review 7.  Epigenetics and chromatin remodeling in adult cardiomyopathy.

Authors:  Salma Awad Mahmoud; Coralie Poizat
Journal:  J Pathol       Date:  2013-10       Impact factor: 7.996

8.  Phosphoproteomics Identifies CK2 as a Negative Regulator of Beige Adipocyte Thermogenesis and Energy Expenditure.

Authors:  Kosaku Shinoda; Kana Ohyama; Yutaka Hasegawa; Hsin-Yi Chang; Mayu Ogura; Ayaka Sato; Haemin Hong; Takashi Hosono; Louis Z Sharp; David W Scheel; Mark Graham; Yasushi Ishihama; Shingo Kajimura
Journal:  Cell Metab       Date:  2015-11-08       Impact factor: 27.287

Review 9.  Lysine acetyltransferases and lysine deacetylases as targets for cardiovascular disease.

Authors:  Peng Li; Junbo Ge; Hua Li
Journal:  Nat Rev Cardiol       Date:  2019-07-26       Impact factor: 32.419

10.  Phospho-Proteomic Analysis of Cardiac Dyssynchrony and Resynchronization Therapy.

Authors:  Marisa J Stachowski; Ronald J Holewinski; Eric Grote; Vidya Venkatraman; Jennifer E Van Eyk; Jonathan A Kirk
Journal:  Proteomics       Date:  2018-08-30       Impact factor: 3.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.